Medicine and Dentistry
Sickle-Cell Disease
100%
Cord Blood
100%
Reduced Intensity Conditioning
100%
Phase I Trials
100%
Cord Blood Stem Cell Transplantation
100%
Engraftment
60%
Virus Infection
40%
Disease Free Survival
40%
Acute Graft Versus Host Disease
40%
Patient with Sickle Cell Disease
40%
Thiotepa
40%
Immunosuppressive Treatment
20%
Survival Rate
20%
Overall Survival
20%
Graft Versus Host Reaction
20%
Hematopoietic Stem Cell Transplantation
20%
Conditioning
20%
Epstein Barr Virus
20%
Cytomegalovirus
20%
Prophylaxis
20%
Adenoviridae
20%
Graft Rejection
20%
Hydroxyurea
20%
Calcineurin Inhibitor
20%
Chronic Graft Versus Host Disease
20%
Human Respiratory Syncytial Virus
20%
Alemtuzumab
20%
Fludarabine
20%
Melphalan
20%
Mycophenolate Mofetil
20%
Keyphrases
Sickle Cell Disease
100%
Reduced-intensity Conditioning
100%
Phase I Trial
100%
Unrelated Cord Blood Transplantation
100%
Graft-versus-host Disease (GvHD)
50%
Disease-free Survival
33%
Viral Infection
33%
Thiotepa
33%
Hematopoietic Stem Cell Transplantation
16%
Adenovirus
16%
Overall Survival
16%
Infectious Diseases
16%
In(III)
16%
Cerebrovascular Accident
16%
Graft Rejection
16%
Cytomegalovirus
16%
Calcineurin Inhibitors
16%
Mycophenolate Mofetil
16%
Epstein-Barr Virus
16%
Child Age
16%
Engraftment
16%
Rejection Rate
16%
Respiratory Syncytial Virus
16%
Hydroxyurea
16%
Alemtuzumab
16%
Donor Engraftment
16%
HLA-matched Donor
16%
HLA Matching
16%
DRB1
16%
Fludarabine
16%
Graft-versus-host Disease Prophylaxis
16%
Melphalan
16%
Systemic Immunosuppression
16%
Donor Cells
16%
Cell Engraftment
16%
Autologous Recovery
16%
Immunology and Microbiology
Sickle Cell
100%
Umbilical Cord Blood
100%
Cord Blood Stem Cell Transplantation
100%
Engraftment
50%
Conditioning
50%
Disease Free Survival
33%
Viral Disease
33%
Acute Graft Versus Host Disease
33%
Chronic Graft Versus Host Disease
16%
Hematopoietic Stem Cell Transplantation
16%
Graft-Versus-Host Disease
16%
Immunosuppression
16%
Overall Survival
16%
Survival Rate
16%
Adenoviridae
16%
Cytomegalovirus
16%
Human Respiratory Syncytial Virus
16%
Alemtuzumab
16%
Mycophenolate Mofetil
16%
Epstein Barr Virus
16%